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Abstract
We synthesized novel ubiquinone analogs by hybridizing the natural ubiquinone ring (2,3-dimethoxy-5-methyl-1,4-benzoquinone) and
hydrophobic phenoxybenzamide unit, and named them hybrid ubiquinones (HUs). The HUs worked as electron transfer substrates with
bovine heart mitochondrial succinate–ubiquinone oxidoreductase (complex II) and ubiquinol–cytochrome c oxidoreductase (complex III),
but not with NADH–ubiquinone oxidoreductase (complex I). With complex I, they acted as inhibitors in a noncompetitive manner against
exogenous short-chain ubiquinones irrespective of the presence of the natural ubiquinone ring. Elongation of the distance between the
ubiquinone ring and the phenoxybenzamide unit did not recover the electron accepting activity. The structure/activity study showed that high
structural specificity of the phenoxybenzamide moiety is required to act as a potent inhibitor of complex I. These findings indicate that
binding of the HUs to complex I is mainly decided by some specific interaction of the phenoxybenzamide moiety with the enzyme. It is of
interest that an analogous bulky and hydrophobic substructure can be commonly found in recently registered synthetic pesticides the action
site of which is mitochondrial complex I.
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1. Introduction
A large number of inhibitors of mitochondrial NADH–
ubiquinone oxidoreductase (complex I) are known [1–3].
With the exception of rhein [4] and diphenyleneiodonium
[5], which inhibit electron input into complex I, all inhib-
itors act at the terminal electron transfer step of this enzyme.
Radioligand binding [6] and photoaffinity labeling [7]
studies indicated that a wide variety of structurally different
inhibitors act at a common binding domain in complex I.
These findings suggest that the domain is a large cavity-like
structure that enables occupation by a variety of inhibitors
in a dissimilar manner depending on their structural specif-
icity, in analogy with different types of Qo center inhibitors
of the cytochrome bc1 complex (ubiquinol–cytochrome c
oxidoreductase—complex III) [8]. Recent mutagenesis
studies using the yeast Yarrowia lipolytica and Rhodobacter
capsulatus suggested that both PSST and 49-kDa subunits
contribute to the inhibitor binding domain and ligate iron–
sulfur cluster N2 [9–11]. It should, however, be realized
that there is still no hard experimental evidence to verify
whether the inhibitors of the terminal electron transfer step
indeed occupy the ubiquinone reduction site.
Some complex I inhibitors, such as piericidin A and
capsaicin, are certainly analogous in chemical structure to
the ubiquinone molecule. However, taking into consideration
the fact that these inhibitors do not block all the ubiquinone
redox sites of mitochondrial respiratory enzymes, one should
not necessarily conclude that an inhibitor which is chemi-
cally analogous to ubiquinone occupies the ubiquinone
reduction site of complex I. In this context, an inhibitor that
possesses the natural ubiquinone ring itself (i.e., 2,3-dime-
thoxy-5-methyl-1,4-benzoquinone) could be useful to probe
the structural and functional characteristics of the ubiquinone
reduction site of the enzyme, although no such chemical has
been described to date. In the present study, we synthesized
novel ubiquinone analogs by hybridizing the natural ubiq-
uinone ring and hydrophobic phenoxybenzamide unit (N-
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methyl-4-(4-tert-butylphenoxy)benzamide), and named
them hybrid ubiquinones (HUs, see Fig. 1). The phenox-
ybenzamide unit was chosen as a partner of the ubiquinone
ring as this structural unit was expected to enhance the
affinity of the ligand to complex I, as discussed later. The
electron transfer and/or inhibitory efficiencies of HUs with
bovine heart mitochondrial complexes I, II and III were
investigated.
2. Materials and methods
2.1. Materials
MOA-stilbene was provided by Aburahi Laboratories,
Shionogi (Shiga, Japan). Piericidin A was provided by Dr.
Shigeo Yoshida (RIKEN, Japan).
2.2. Synthesis
2.2.1. Intermediates 1a, 1b and 1c
N-Methyl-4-bromobenzamide was prepared by reacting
4-bromobenzoyl chloride and methylamine hydrochloride in
the presence of K2CO3 in a water/Et2O mixture (1:1) at 0 jC
(Fig. 2). Intermediate 1a was synthesized by reacting N-
methyl-4-bromobenzamide and 4-tert-butylphenol in the
presence of a catalytic amount of Cu at 160 jC for 3 h.
1H NMR (300 MHz, CDCl3) y 1.33 (s, 9H), 3.00 (d, J = 4.8
Hz, 3H), 6.08 (br s, 1H), 6.96 (m, 4H), 7.37 (m, 2H), 7.71
(m, 2H) (Fig. 2).
Intermediates 1b (R =Et) and 1c (R =H) were prepared by
the same procedures, except that ethylamine hydrochloride
and ammonium chloride were used in place of methylamine
hydrochloride, respectively. 1b: 1H NMR (300 MHz, CDCl3)
y 1.25 (t, J = 7.2 Hz, 3H), 1.33 (s, 9H), 3.49 (dq, J = 6.0, 7.2
Hz, 2H), 6.05 (br s, 1H), 6.96 (m, 4H), 7.37 (m, 2H), 7.72
(m, 2H). 1c: 1H NMR (300 MHz, CDCl3) y 1.34 (s, 9H),
5.85 (br s, 1H), 6.98 (m, 4H), 7.38 (m, 2H), 7.77 (m, 2H).
2.2.2. Intermediates 2, 3 and 4
Intermediate 2 was synthesized as described previously
[13]. Intermediate 3 was obtained by reacting intermediate 2
and NaCN in the presence of triethylbenzylammonium
chloride (0.05 molar equiv.) in an acetone/water mixture
(8:3) at 90 jC overnight. 1H NMR (300 MHz, CDCl3) y
2.26 (s, 3H), 3.67 (s, 2H), 3.79 (s, 3H), 3.90 (s, 3H), 3.92
(s, 3H), 3.95 (s, 3H). Intermediate 4 was prepared by the
reduction of intermediate 3 with LiAlH4 in dry THF at room
temperature (r.t.). 1H NMR (300 MHz, CDCl3) y 1.47 (br s,
2H), 2.18 (s, 3H), 2.80 (m, 4H), 3.78 (s, 3H), 3.83 (s, 3H),
3.89 (s, 3H), 3.92 (s, 3H).
2.2.3. HU-1, HU-2, HU-3, HU-5 and HU-8
To a solution of intermediate 1 (0.2 g, 0.71 mmol)
in DMSO (7 ml) was added NaH (20 mg, 0.83 mmol),
and the mixture was stirred at r.t. for 1 h. To the re-
action mixture was added a solution of intermediate 2
(0.26 g, 0.85 mmol) in DMSO (1 ml) dropwise and stirred
at r.t. for 1 h. The reaction mixture was extracted with ethyl
acetate and washed with brine. The crude product was
purified by silica gel column chromatography (ethyl ace-
tate/hexane = 7:3) to give the precursor of HU-1 in an 84%
yield. The precursor was oxidized by ceric ammonium
nitrate (CAN) to give HU-1 as described previously [14].
1H NMR (300 MHz, CDCl3) y 1.33 (s, 9H), 2.19 (br s, 3H),
3.03 (br s, 3H), 4.00 (s, 3H), 4.03 (s, 3H), 4.55 (br s, 2H),
6.97 (m, 4H), 7.36 (m, 4H). ESIMS m/z 478 [M+H] +.
HU-2 and HU-3 were synthesized by the same proce-
dures, except that intermediates 1b and 1c were used,
respectively, in place of intermediate 1a. HU-2: 1H NMR
(300 MHz, CDCl3) y 1.12 (t, J = 7.0 Hz, 3H), 1.33 (s, 9H),
2.18 (br s, 3H), 3.42 (q, J = 7.0 Hz, 2H), 4.00 (s, 3H), 4.02
(s, 3H), 4.53 (br s, 2H), 6.96 (m, 4H), 7.32 (m, 4H). ESIMS
m/z 492 [M+H] + . HU-3: 1H NMR (300 MHz, CDCl3) y
Fig. 1. Structures of HUs synthesized in this study.
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1.33 (s, 9H), 2.30 (s, 3H), 3.98 (s, 3H), 4.01 (s, 3H), 4.46 (d,
J = 6.3 Hz, 2H), 6.70 (br t, J = 6.3 Hz, 1H), 6.96 (m, 4H),
7.37 (d, J = 8.7 Hz, 2H), 7.69 (d, J = 8.7 Hz, 2H). ESIMS
m/z 486 [M+Na] +.
HU-5 was synthesized by the same procedures, except
that N-methyl-4-(4-n-butylphenoxy)benzamide was used in
place of N-methyl-4-(4-tert-butylphenoxy)benzamide. 1H
NMR (300 MHz, CDCl3) y 0.94 (t, J = 7.3 Hz, 3H), 1.36
(sext, J = 7.2 Hz, 2H), 1.60 (m, 2H), 2.19 (br s, 1H), 2.60 (t,
J = 15 Hz, 2H), 3.03 (br s, 3H), 4.00 (s, 3H), 4.03 (s, 3H),
4.55 (br s, 2H), 6.95 (m, 4H), 7.15 (m, 2H), 7.37 (m, 2H).
ESIMS m/z 478 [M+H] +.
HU-8 was synthesized by the same procedures, except
that N-methylundecanamide was used in place of intermedi-
ate 1a. 1H NMR (300 MHz, CDCl3) y 0.88 (t, J = 6.5 Hz,
3H), 1.22–1.38 (m, 14H), 1.58 (m, 2H), 2.15 (s, 3H), 2.27
(t, J = 7.5 Hz, 2H), 3.02 (s, 3H), 3.98 (s, 3H), 4.01 (s, 3H),
4.40 (s, 2H). ESIMS m/z 416 [M+Na] +.
2.2.4. HU-4
Intermediate 3 was driven to acid chloride by hydrolysis
with KOH in 1-butanol/water (1:1) followed by SOCl2
treatment in toluene at 70 jC. To a solution of 4-(4-tert-
butylphenoxy)aniline (0.92 g, 3.8 mmol) and triethylamine
(0.93 g, 9.2 mmol) in dry CH2Cl2 was added a solution of
crude 2,3,4,5-tetramethoxy-6-methylphenylacetyl chloride
in CH2Cl2, and the reaction mixture was stirred at r.t. for
10 h. After working up the reaction mixture, the crude
product was purified by silica gel column chromatography
(ethyl acetate/hexane = 3:7) to give N-4-(4-tert-butylphe-
noxy)phenyl-2-(2,3,4,5-tetramethoxy-6-methyl)phenyletha-
namide in an 87% yield. N-Methylation of this product
using CH3I and NaH, and sequential oxidation by CAN
afforded HU-4 in a 65% yield. 1H NMR (300 MHz, CDCl3)
y 1.33 (s, 9H), 1.98 (br s, 3H), 3.25 (br s, 3H), 3.27 (br s,
2H), 3.97 (s, 3H), 3.99 (s, 3H), 6.99 (m, 4H), 7.28 (m, 2H),
7.38 (m, 2H). ESIMS m/z 500 [M+Na] +.
2.2.5. HU-6
To a solution of intermediate 4 (0.14 g, 0.55 mmol) and
triethylamine (0.11 g, 1.1 mmol) in 20 ml of CH2Cl2 was
added a solution of 4-(4-tert-butylphenoxy)benzoylchloride
(0.16 g, 0.55 mmol) in CH2Cl2 (2 ml) dropwise at 0 jC and
the mixture was stirred at r.t. overnight. The reaction
mixture was extracted with ethyl acetate and washed with
1 N HCl, saturated sodium bicarbonate solution and brine.
The crude product was purified by silica gel column chro-
matography (ethyl acetate/hexane = 1:1) to give the amide
intermediate in a 60% yield. N-Methylation and sequential
oxidation of this amide by the procedures described above
afforded HU-6 in a 45% yield for two steps. 1H NMR (300
MHz, CDCl3) y 1.33 (s, 9H), 1.76 (br s, 1H), 2.17 (br s,
2H), 2.69 (br s, 0.6 H), 2.86 (br s, 1.4 H), 3.08 (br s, 3H),
3.43 (br s, 0.6 H), 3.58 (br s, 1.4 H), 3.99 (s, 6H), 6.96 (m,
4H), 7.36 (m, 4H). ESIMS m/z 514 [M+Na] +.
2.2.6. HU-7
To a mixture of tetrahydro-2-(4-pentynyloxy)-2H-pyrane
(0.94 g, 5.6 mmol) and CuI (1.06 g, 5.6 mmol) in dry THF
(7 ml) was added 4.5 ml of n-BuLi (1.50 M, 6.7 mmol)
dropwise at  78 jC and stirred for 20 min. To the mixture
was added 1.2 ml of hexamethylphosphoric triamide and
Fig. 2. Reaction conditions; (a) CH3NH3
+Cl , C2H5NH3
+Cl , or NH4
+Cl , K2CO3, H2O–Et2O; (b) tert-butylphenol, K2CO3, Cu; (c) NaCN,
triethylbenzylammonium chloride, acetone–H2O; (d) LiAlH4, THF; (e) NaH, DMSO; (f) ceric ammonium nitrate, CH3CN–H2O; (g) (i) KOH, n-butanol–
H2O, (ii) SOCl2, DMF, toluene; (h) Et3N, CH2Cl2; (i) CH3I, NaH, Et3N, DMSO; (j) n-BuLi, CuI, HMPA, THF; (k) (i) p-toluenesulfonic acid, MeOH, (ii) H2,
Pd/C, (iii) MsCl, Et3N, THF.
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stirred for 30 min at  78 jC. A solution of intermediate 2
(1.14 g, 3.73 mmol) in 10 ml of dry THF was added to the
mixture dropwise, and the mixture was allowed to warm to
r.t. over a period of 1 h. The reaction mixture was quenched
with saturated ammonium chloride solution, extracted with
Et2O and washed with brine. The crude product was
purified by silica gel column chromatography (ethyl ace-
tate/hexane = 15:85) to give intermediate 5 in a 58% yield.
Deprotection of the THP group was achieved by p-toluene-
sulfonic acid in MeOH. The alcohol was hydrogenated with
10% palladium on carbon in EtOH under hydrogen gas. The
resulting saturated alcohol was mesylated in the presence of
triethylamine in dry THF to afford intermediate 6. Amide
formation, N-methylation, and sequential oxidation were
carried out by the procedures described for HU-1 to afford
HU-7. 1H NMR (300 MHz, CDCl3) y 1.33 (s, 9H), 1.25–
1.70 (m, 8H), 2.00 (br s, 3H), 2.44 (br s, 2H), 3.02 (br s,
3H), 3.28 (br s, 1H), 3.50 (br s, 1H), 3.99 (s, 6H), 6.97 (m,
4H), 7.36 (m, 4H). ESIMS m/z 548 [M+H] +.
2.3. Electron transfer activity in submitochondrial particles
Bovine heart submitochondrial particles (SMP) were
prepared by the method of Matsuno-Yagi and Hatefi [12]
using a sonication medium containing 0.25 M sucrose, 1
mM succinate, 1.5 mM ATP, 10 mM MgCl2, 10 mM MnCl2
and 10 mM Tris–HCl (pH 7.4), and stored in a buffer
containing 0.25 M sucrose and 10 mM Tris–HCl (pH 7.4)
at  82 jC.
The NADH–HU oxidoreductase activity in SMP was
determined following NADH oxidation at 30 jC with a
Shimadzu UV-3000 (340 nm, e = 6.2 mM 1 cm  1). The
reaction medium (2.5 ml) contained 0.25 M sucrose, 1 mM
MgCl2, 0.2 AM antimycin A, 0.2 AM MOA-stilbene and 2
mM KCN and 50 mM phosphate buffer (pH 7.4). The final
mitochondrial protein concentration was 30 Ag of protein/
ml. After equilibration of SMP with the HU, the reaction
was started by the addition of 50 AM NADH.
The inhibition of NADH–decyl ubiquinone (DB) oxi-
doreductase activity by HUs was determined under the same
experimental conditions, except that the 50 AM DB was
used as a substrate. The reaction was started by adding 50
AM NADH after equilibration of SMP with HU for 5 min.
The succinate–HU oxidoreductase activity was coupled
to the reduction of DCIP (e = 21 mM 1 cm  1), and the rate
was followed spectrophotometrically at 600 nm and 30 jC.
The reaction medium contained 0.25 M sucrose, 20 mM
succinate, 2.0 mM KCN, 1.0 mM MgCl2, 1 AM rotenone,
0.1 AM antimycin A, 50 AM DCIP, and 50 mM phosphate
buffer (pH 7.4). The final mitochondrial protein concen-
tration was 30 Ag of protein/ml. The effects of HUs on
succinate–Q2 oxidoreductase activity was examined under
the same experimental conditions, except that 50 AM Q2
was used as a substrate.
The HUH2–cytochrome c oxidoreductase activity was
measured at 30 jC as the rate of cytochrome c reduction
with the wavelength pair 550–540 nm (e = 19 mM  1
cm  1). SMP were treated with sodium deoxycholate (0.2
mg/mg of protein) before dilution with reaction medium.
The reaction medium contained 0.25 M sucrose, 2.0 mM
KCN, 1.0 mMMgCl2, 1 AM rotenone, 50 AM cytochrome c,
and 50 mM phosphate buffer (pH 7.4). The reaction was
started by adding HUH2. The final mitochondrial protein
concentration was 30 Ag of protein/ml. The effects of
HUH2s on Q2H2–cytochrome c oxidoreductase activity
was examined under the same experimental conditions,
except that 50 AM Q2H2 was used as a substrate.
3. Results
3.1. Design concept of HUs
The design strategy for the HU is illustrated in Fig. 3.
The N-methyl-4-(4-tert-butylphenoxy)benzamide unit was
chosen as a partner for the ubiquinone ring since this
structural unit markedly enhances the affinity of synthetic
capsaicin derivatives to bovine heart mitochondrial complex
I [6,15], as shown such a potent capsaicin analog as an
example. If the phenoxybenzamide unit, in general, supports
Fig. 3. Design concept of HUs. The synthetic capsaicin possessing the N-
methyl-4-(4-tert-butylphenoxy)benzamide unit has a much higher affinity
to complex I than natural capsaicin. The isoprenyl tail of ubiquinone was
replaced by the N-methyl-4-(4-tert-butylphenoxy)benzamide unit which is
expected to enhance the affinity of the ligand to complex I.
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tight binding of the ligand to complex I regardless of the
remaining structure, HU is expected to bind to the enzyme
with high affinity.
We synthesized eight HUs shown in Fig. 1. HU-1 was
prepared as a lead compound, wherein the ubiquinone ring
and N-methyl-4-(4-tert-butylphenoxy)benzamide unit were
directly linked. To examine the function of the N-Me amide
group, HU-2, HU-3 and HU-4 were synthesized. HU-5
possessing an n-butyl group in place of the tert-butyl group
was prepared to examine the effect of bulkiness of the
substituent attached to the benzene ring. To vary the
distance between the ubiquinone ring and N-methyl-4-(4-
tert-butylphenoxy)benzamide moiety, HU-6 and HU-7 were
synthesized. In addition, to know the effect of hydrophobic
phenoxyphenyl moiety, HU-8 possessing a long alkyl chain
was prepared.
3.2. Effects of HUs on complex I activity
The electron accepting efficiency of HUs was examined
by NADH–HU oxidoreductase assay with complex I in
SMP (Table 1). No HUs, except HU-8, elicited any electron
accepting activity at all, indicating that the hydrophobic
phenoxyphenyl group is quite unfavorable for electron
accepting activity. HU-8, which carries a long alkyl chain
in place of the phenoxyphenyl group, worked as a substrate,
although the electron accepting activity in terms of the Vmax
value was about one-third that of DB. Considering that HU-
8 possesses a long alkyl tail as does DB, the presence of a
polar amide group in the tail is not preferable for electron
accepting activity. This result is consistent with our previous
finding that the role of the alkyl tail of short chain ubiq-
uinones is not only to enhance the hydrophobicity of the
ubiquinone molecule, but to contribute to some specific
interaction with complex I [13]. The electron accepting
activity of HU-8 was almost completely (>95%) inhibited
by 0.1 AM piericidin A.
To elucidate whether HU-1 to HU-7 act as inhibitors of
complex I, their effect on NADH–DB oxidoreductase
activity was examined. Inhibitory potencies in terms of the
IC50 value, which is the molar concentration needed to halve
the control enzyme activity, are listed in Table 1. The
inhibition of complex I activity by HUs at sufficiently high
concentrations took place immediately as is the case of
ordinary complex I inhibitors. Among 4-(4-tert-butylphe-
noxy)benzamide derivatives (HU-1 to HU-3), the N–Me
derivative (HU-1) was the most potent inhibitor. The order
of N–Me and CjO (–NMeCO– or –CONMe–) appeared
to significantly affect the activity (HU-1 vs. HU-4).
Replacement of the tert-butyl group by the n-butyl group
resulted in a marked decrease in inhibitory potency, regard-
less of the same number of carbon atoms (HU-1 vs. HU-5).
Furthermore, elongation of the distance between the ubiq-
uinone ring and the phenoxybenzamide moiety also signifi-
cantly diminished the inhibitory activity (HU-1 vs. HU-6
and HU-7). Thus, it is obvious that when HU-1 binds to
complex I, the N-methyl-4-(4-tert-butylphenoxy)benzamide
unit and its position relative to the ubiquinone ring are
strictly recognized by the enzyme.
Next, we examined the inhibitory effect of the reduced
form of HUs on NADH–DB oxidoreductase activity (Table
1). The reduced form was prepared by the ordinary method
of Rieske [16]. The structure/activity profiles for the
reduced form were comparable to those for the oxidized
form, indicating that the redox form of the ubiquinone ring
has no or, at least, only a slight effect on the inhibitory
action of HUs. This result also indicates that the inhibitory
action of HUs is mainly decided by the phenoxybenzamide
moiety rather than the ubiquinone ring. In support of this
idea, solely N,N-dimethyl-4-(4-tert-butylphenoxy)benza-
mide (DMBA in Fig. 1) elicited inhibition, though its
potency was less than that of HU-1.
Although HU-8 served as an electron acceptor, both
the oxidized and the reduced forms of this compound
showed, at the same time, apparent inhibition of NADH–
DB oxidoreductase activity at high concentrations (Table
1). This apparent inhibition by the oxidized and the re-
duced forms is likely due to a low turnover number and
product inhibition, respectively, as is the case for the inhi-
bition of NADH–Q1 oxidoreductase activity by Q2 and
Q2H2 [13,14,17].
Table 1






















HU-1 0.077 0.088 0.36 0.028 – 26%b
HU-2 0.37 0.63 0.90 0.023 4.0 0.50
HU-3 0.34 0.53 – < 5%c 2.1 0.91
HU-4 1.8 2.0 1.2 0.010 9.4 0.64
HU-5 0.97 0.84 0.76 0.017 3.8 1.0
HU-6 0.47 0.76 1.3 0.049 – < 5%b
HU-7 1.1 0.61 2.0 0.011 5.5 1.1
HU-8d 11.8 6.2 33 0.028 – 19%b
DMBA 0.65
Piericidin A 0.003
Q2 (or Q2H2) 0.36 0.11 1.6 5.2
a The inhibitory potency in terms of the IC50, which is the molar
concentration needed to halve the control enzyme activity, was obtained
from two independent experiments.
b The kinetic parameters could not be accurately estimated due to
substrate inhibition at high concentration range. The maximum reaction rate
normalized by the Vmax value of Q2H2 is listed.
c The kinetic parameters could not be accurately estimated due to very
poor activity. The maximum reaction rate normalized by the Vmax value of
Q2 is listed.
d The electron accepting activity of HU-8 for complex I in terms of the
Vmax value is about one-third that of DB.
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3.3. Effects of HUs on complexes II and III activities
The electron accepting efficiencies of HUs were exam-
ined with succinate–ubiquinone oxidoreductase (complex
II) in SMP (Table 1). All HUs worked as electron acceptors,
though the efficiency varied widely depending upon struc-
ture. The kinetic parameters of HU-3 could not be accu-
rately estimated due to very poor activity. The Km value of
HU-8 was markedly larger than that of the phenoxybenza-
mide derivatives. Some HUs showed slight inhibition of
succinate–Q2 oxidoreductase activity at high concentration
range due to competition for the Q2 binding site, as reported
for other ubiquinone analogs being poor electron acceptors
[13,14,18].
The electron transfer activities of HUs were also exam-
ined with complex III in SMP using the reduced form of
HUs (Table 1). In this assay, electron donating activity is
mainly evaluated since the ubiquinol oxidation at the Qo site
is a rate-limiting step in the overall reaction of complex III
[19]. All HUs elicited electron donating activity, though
substrate inhibition was observed at high concentration
range for HU-1, HU-6 and HU-8. The reduced form of
some HUs showed slight inhibition of Q2H2–cytochrome c
oxidoreductase activity at high concentration range due to
competition for the Q2H2 binding site, as is the case for
complex II assay.
4. Discussion
The HUs, except HU-8, worked as specific inhibitors
solely with complex I. HU-1 is the most potent inhibitor
among the HUs synthesized in this study. Structural mod-
ification of the N-methyl-4-(4-tert-butylphenoxy)benzamide
unit of HU-1 markedly decreased the inhibitory potency,
regardless of the redox form of the ubiquinone ring.
Expectedly, this structural unit appears to enhance the
binding affinity of the ligand to complex I. Elongation of
the distance between the N-methyl-4-(4-tert-butylphenox-
y)benzamide unit and the ubiquinone ring up to six meth-
ylene units (HU-7) did not recover the electron accepting
activity. It is therefore obvious that irrespective of the
presence of the natural ubiquinone ring in the molecule,
the binding of HU-1 to complex I is mainly decided by
some specific interaction of the N-methyl-4-(4-tert-butyl-
phenoxy)benzamide unit with the enzyme. However, this
does not necessarily exclude a contribution by the ubiq-
uinone ring to the inhibitor binding to the enzyme. The
ubiquinone ring, particularly the two carbonyl groups,
would behave like the polar substructure which is com-
monly found in many complex I inhibitors such as the
heterocyclic ring of piericidin A and synthetic pesticides
shown in Fig. 4.
The above argument leads to the question of whether the
natural ubiquinone ring of HU-1 to HU-7 binds to the
physiological ubiquinone reduction site of complex I. If the
ubiquinone ring occupies the substrate site, at least one of
the following two phenomena would be observed. Firstly,
HUs would show electron accepting activity at least to a
certain extent, as observed for complexes II and III; and
secondly, competitive inhibition pattern of HUs against an
exogenous ubiquinone would be observed, in analogy of
the case of another series of ubiquinone analogs being poor
electron acceptors [13,14]. Regarding the first phenom-
enon, this is not the case as described in the results. To
elucidate the second, we examined the inhibition pattern of
HUs by Lineweaver–Burk plots of the kinetic data of
NADH–DB (or Q1) oxidoreductase activity in the presence
of HU-1 or HU-6. The inhibition pattern of both HUs was
noncompetitive against both exogenous ubiquinones, as
Fig. 4. Structure of Pyridaben (Nissan Chemical Industries), Tebfenpyrad
(Mitsubishi Chemical), and Fenazaquin (Dow Elanco).
Fig. 5. Lineweaver–Burk plot of NADH–DB oxidoreductase activity in
the presence of 0 M (o), 9.6 nM (.), or 19 nM (5) of HU-1.
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shown in Fig. 5 taking the pair of DB and HU-1 as an
example. It should be mentioned that the inhibition pattern
of HU-8, a poor electron acceptor, was competitive against
both exogenous ubiquinones (data not shown). These
results along with the above structure/activity study
strongly suggest that the binding site of HUs carrying the
phenoxybenzamide moiety does not overlap with the ubiq-
uinone reduction site.
On the other hand, as our assays for complex I activity
were performed under steady-state conditions, we cannot
entirely rule out the possibility that the ubiquinone part of
HUs accepts two electrons from the ubiquinone reduction
site in complex I without further electron transfer event.
However, we consider this option as unlikely since it seems
difficult to suppose that the reduced form of HUs does not
leave the ubiquinone reduction site.
Complex I inhibitors are expected to hold important
positions in most modern synthetic insecticides and acar-
icides [20,21]. In fact, a number of chemical companies
have recently announced new complex I inhibitors meeting
the many standards required for safe agrochemicals [3].
The present and a previous [15] study showed that the N-
methyl-4-(4-tert-butylphenoxy)benzamide unit generally
enhances the binding affinity of the ligand to complex I.
It is of interest that a bulky and hydrophobic substructure
analogous to HUs (i.e., tert-butylbenzene) can be com-
monly found in recently registered synthetic pesticides, as
shown in Fig. 4. These chemicals are also potent inhibitors
of bovine complex I [3,6,7]. Thus, a bulky and hydro-
phobic substructure is desirable in an inhibitor acting at the
terminal electron transfer step of complex I. This informa-
tion is helpful for designing novel inhibitors of the en-
zyme.
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